MobilityAPP: Baseline characterization of daily-life mobility in patients with atypical Parkinsonian disorders

Résumé fourni par la source

Data usage and citation This dataset accompanies the study “Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders”, published in npj Parkinson's Disease. When using this dataset, users are kindly requested to cite both the dataset itself using the Zenodo citation/DOI and the associated publication: Associated publication:Moradi et al., “Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders.” npj Parkinson's Disease. DOI: 10.1038/s41531-025-01242-2. Please use the citation provided by Zenodo for the dataset itself. Dataset Description for Zenodo This dataset contains comprehensive clinical, instrumented gait, and real-world physical activity data from 84 patients with Parkinson’s disease (PD) and atypical Parkinsonian disorders (APD), including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). It was collected as part of the MobilityAPP Study (ClinicalTrials.gov: NCT04608604), which aimed to move beyond traditional clinical assessments and provide in-depth quantification of mobility in both laboratory and daily-life settings. Data Overview 1. Clinical Assessments Demographic and disease characterization, including age, disease duration, and motor impairment. Standardized clinical evaluations, including Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Hoehn and Yahr (H&Y) staging. Column names of the clinical_data file, Center: Study center at which the participant's clinical and gait recording were performed (coded). SCR: Screening BL: Baseline (the Screening visit occurred 1 week before the Baseline visit) LEDD: Levodopa equivalent daily dose CGI_S: Clinical Global Impression-Severity (CGI-S) score, representing clinician-rated overall disease severity PGI_S: Patient Global Impression-Severity (PGI-S) score, representing patient-rated overall disease severity FAB: Frontal Assessment Battery total score F_NF_BL: 0 means no falls or only 1 fall during the period of screening to the Baseline visit 1 means more than 1 fall during the period of screening to the Baseline visit MoCA: Montreal Cognitive Assessment total score BBS: Berg Balance Scale OH: Orthostatic Hypotension FOG_Q: Freeze of Gait Questionnaire PDQ_8: Parkinson's Disease Questionnaire-8 IPAQ: International Physical Activity Questionnaire PSPRS: Progressive Supernuclear Palsy Rating Scale UMSARS: Unified Multipple System Athrophy RAting Scale 2. Instrumented Gait Analysis (IGA) Laboratory gait recordings acquired under controlled conditions using wearable IMU sensors during structured tests such as the 2 × 10 m walk in the clinic. Spatio-temporal gait metrics (e.g., gait velocity, stride length, stride time, asymmetry, variability). Additionally, we provide the asymmetry of the parameters, which were calculated based on the definition in the paper (10.1038/s41531-025-01242-2). The Timed-Up-and-Go (TUG) file. 3. Physical Activity Monitoring (PAM) Continuous monitoring of daily-life mobility using wearable sensors worn at home over ≥3 valid days (≥8 h/day). Metrics derived from natural walking patterns such as step counts, walking bout durations, cadence, and moderate-to-vigorous physical activity (MVPA). Cohort and Data Structure 84 participants with complete datasets after quality control (41 PD, 23 MSA, 20 PSP). Clinical data: demographics, MDS-UPDRS, H&Y, cognitive and balance scores. Sensor data: gait parameters from IGA and PAM. Data are structured for ease of integration with statistical tools or machine learning workflows, allowing researchers to explore relationships between clinical severity and quantitative mobility biomarkers. Scientific Value This dataset bridges the gap between standard clinical ratings and objective digital mobility metrics by combining controlled gait laboratory measurements with real-world activity patterns. It enables investigations into: The association between clinical severity and gait performance. Distinctions in mobility profiles across PD and atypical Parkinsonian syndromes. Development and validation of digital biomarkers using both structured and unstructured movement data. Notes on ethics/study context Data were collected as part of a prospective clinical study registered at ClinicalTrials.gov (NCT04608604). All participants provided written informed consent, and the study was approved by the local ethics committee.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.